SCHEMBL6260508

SCHEMBL6260508

O=C1NC(=O)c2cc(NC(=O)C(F)(F)F)ccc21

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.68
HSD17B10 Q99714 2/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
ALDH1A1 P00352 5/20 0.59
GLA P06280 1/20 0.59
CTDSP1 Q9GZU7 2/20 0.58
POLB P06746 1/20 0.58
HPGD P15428 3/20 0.56
KMT2A Q03164 6/20 0.56
MEN1 O00255 3/20 0.56
RXFP1 Q9HBX9 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ALOX12 P18054 1/20 0.54
PKM P14618 2/20 0.52
CASP3 P42574 2/20 0.51
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6263755 0.82 KDM4E (1.00) KDM4EHSD17B10SMN1; SMN2ALDH1A1GLA
SCHEMBL4462900 0.80 KDM4E (0.66) KDM4EHSD17B10ALDH1A1GLACTDSP1
SCHEMBL13256671 0.79 KDM4E (0.62) KDM4EHSD17B10SMN1; SMN2ALDH1A1GLA
SCHEMBL5838218 0.78 ALDH1A1 (0.69) KDM4EHSD17B10SMN1; SMN2ALDH1A1GLA
SCHEMBL30057929 0.77 MKNK1 (0.48) KDM4EHSD17B10SMN1; SMN2ALDH1A1GLA
SCHEMBL22079528 0.77 KMT2A (0.71) KDM4EHSD17B10SMN1; SMN2CTDSP1POLB
SCHEMBL22336063 0.76 PTPRC (0.68) SMN1; SMN2ALDH1A1POLBKMT2AMEN1
SCHEMBL20418723 0.76 MKNK1 (0.49) KDM4EHSD17B10SMN1; SMN2
SCHEMBL26695993 0.75 KDM4E (0.65) KDM4EHSD17B10SMN1; SMN2ALDH1A1GLA
SCHEMBL6260497 0.74 CASP3 (0.86) KDM4EALDH1A1GLAPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182061-A1 Phthalimide compounds useful as protein kinase inhibitors GREEN JEREMY (US) 2005-08-18 US claimed
WO-2005039564-A1 PHTHALIMIDE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-05-06 WO claimed
US-20050182061-A1 Phthalimide compounds useful as protein kinase inhibitors GREEN JEREMY (US) 2005-08-18 US disclosed
WO-2005040112-A1 COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY OXAGEN LIMITED (GB) 2005-05-06 WO disclosed
WO-2005039564-A1 PHTHALIMIDE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182061-A1 Phthalimide compounds useful as protein kinase inhibitors PDK1, PDPK1, MTOR KDM4E 793/4885HSD17B10 2659/4885SMN1; SMN2 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.